18F-FES PET能否改善18F-FDG PET对转移性浸润性小叶癌患者的评估?
本研究回顾性分析20例转移性浸润性小叶癌(ILC)患者,同期行18F-FES与18F-FDG PET/CT。18F-FDG对非骨病灶检出率高于18F-FES(57 vs 37,P<0.001),而18F-FES在9/16例骨转移患者中检测骨病灶显著优于18F-FDG(P=0.05)。仅18F-FES阳性病灶的患者(12/12)接受内分泌治疗,无18F-FES摄取者(2/3)主要接受化疗。
要点
- 18F-FDG对非骨病灶检出率高于18F-FES(57 vs 37,P<0.001)。
- 9/16例骨转移患者中18F-FES检测骨病灶显著优于18F-FDG(P=0.05)。
- 仅18F-FES阳性病灶者(12/12)接受内分泌治疗,无摄取者(2/3)主要化疗。
核心结论
- 18F-FES在检测ILC骨转移方面比18F-FDG更有效,但在非骨病灶方面未显示显著优势。
- 18F-FES检查结果有潜力指导患者治疗方案。
研究设计与样本
- 回顾性分析本中心20例接受同期18F-FES与18F-FDG PET/CT检查的ILC患者。
主要发现
- 20例ILC患者中,13例发现65个非骨病灶,16例诊断骨转移并分布于54个骨骼解剖区域。
- 18F-FDG对非骨病灶的检出率高于18F-FES(57 vs 37,P<0.001)。
- 18F-FES在4例患者中检测非骨病灶更优,18F-FDG在5例中更优(P>0.05)。
- 9/16例骨转移患者中,18F-FES检测骨病灶较18F-FDG显示出显著优势(P=0.05)。
- 仅18F-FES阳性病灶的患者(12/12)接受内分泌方案,无18F-FES摄取者(2/3)主要接受化疗。
关键数值与推荐
- 非骨病灶检出率:18F-FDG 57 vs 18F-FES 37(P<0.001)。
- 骨病灶检测:9/16例患者中18F-FES较18F-FDG有显著优势(P=0.05)。
- 非骨病灶优势患者数:18F-FES 4例 vs 18F-FDG 5例(P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Invasive lobular carcinoma (ILC) exhibits a low affinity for 18F-FDG. The estrogen receptor (ER) is commonly expressed in ILCs, suggesting a potential benefit of targeting with the ER probe 18F-FES in this patient population. The objective of this study was to evaluate the diagnostic performance of 18F-FES imaging in patients with metastatic ILC and compare it with that of 18F-FDG. METHODS: We conducted a retrospective analysis of 20 ILC patients who underwent concurrent 18F-FES and 18F-FDG PET/CT examinations in our center. 18F-FES and 18F-FDG imaging were analyzed to determine the total count of tracer-avid lesions in nonbone sites and their corresponding organ systems, assess the extent of anatomical regions involved in bone metastases, and measure the SUVmax values for both tracers. RESULTS: Among 20 ILC patients, 65 nonbone lesions were found to be distributed in 13 patients, and 16 patients were diagnosed with bone metastasis, which was distributed in 54 skeletal anatomical regions. The detection rate of 18F-FDG in nonbone lesions was higher than that of 18F-FES (57 vs 37, P < 0.001). 18F-FES demonstrated a superior ability to detect nonbone lesions in 4 patients, whereas 18F-FDG was superior in 5 patients (P > 0.05). Among 9/16 patients with bone metastasis, 18F-FES demonstrated a significant advantage in the detection of bone lesions compared with 18F-FDG (P = 0.05). Furthermore, patients with only 18F-FES-positive lesions (12/12) were administered endocrine regimens, whereas patients lacking 18F-FES uptake (2/3) predominantly received chemotherapy. CONCLUSIONS: 18F-FES is more effective than 18F-FDG in detecting bone metastasis in ILC, but it does not demonstrate a significant advantage in nonbone lesions. Additionally, the results of examination with 18F-FES have the potential to guide patient treatment plans.
引用
- Liu C, Ma G, Xu X, et al. Can 18F-FES PET Improve the Evaluation of 18F-FDG PET in Patients With Metastatic Invasive Lobular Carcinoma? Clin Nucl Med. 2024. PMID: 38427956. doi:10.1097/RLU.0000000000005085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。